Key Moments
#07 – Deep Dive: Lp(a) — what every doctor, and the 10-20% of the population at risk, needs to know
Peter Attia MDKey Moments
LP(a) is a key cardiovascular risk factor affecting 20% of people, often unknown to doctors. Understanding and managing it is crucial for heart health.
Key Insights
Lp(a) is a particle similar to LDL but with an added apolipoprotein (apoA) that significantly increases cardiovascular risk.
Approximately 20% of the population has elevated Lp(a) levels, yet it's often overlooked by healthcare providers.
Lp(a) contributes to atherosclerosis, aortic stenosis, and venous thromboembolism through mechanisms not fully understood but related to inflammation and clotting.
Measuring Lp(a) particle number is considered more accurate than mass or cholesterol content, with targets generally below 50 nmol/L.
Traditional lipid-lowering therapies like statins do not effectively reduce Lp(a), though PCSK9 inhibitors can lower it by 30-50%.
Newer treatments, such as antisense oligonucleotides (ASOs), directly target Lp(a) synthesis and show significant promise in lowering levels.
WHAT IS LIPOPROTEIN LITTLE A?
Lp(a) is a lipoprotein particle composed of a low-density lipoprotein (LDL) core with an attached apolipoprotein (apoA). It's genetically determined and structurally similar to plasminogen, influencing its role in the body. While LDL is understood to carry cholesterol, Lp(a) carries apoA, which contributes to its unique and problematic properties. The variability in Lp(a) lies in the number of apoA attached to LDL particles and the specific structure of these apoA molecules, particularly the kringle domains.
THE SIGNIFICANCE OF LIPOPROTEIN(A) LEVELS
Elevated Lp(a) levels, found in about 20% of the population, are a significant, often underestimated, risk factor for cardiovascular disease. This particle is linked to an increased incidence of atherosclerosis, aortic stenosis, and venous thromboembolism. Unlike LDL, which can be influenced by lifestyle, Lp(a) levels are primarily genetically determined, making them less responsive to diet and exercise alone. Awareness and measurement of Lp(a) are crucial for comprehensive cardiovascular risk assessment.
MEASUREMENT AND INTERPRETATION OF LIPOPROTEIN(A)
Accurate assessment of Lp(a) risk involves understanding its measurement. While Lp(a) mass and Lp(a) cholesterol have been used, Lp(a) particle number is considered the most informative metric. Levels are typically measured in nmol/L, with values below 50 nmol/L generally considered safe. Higher levels, especially above 100-125 nmol/L, warrant concern. The variability in the apoA structure, particularly the Kringle 4, subsegment 2, influences the mass and particle number, highlighting why particle count is preferred.
LIPOPROTEIN(A)'S ROLE IN CARDIOVASCULAR DISEASE
The problems associated with elevated Lp(a) manifest in three primary ways: accelerated atherosclerosis, increased risk of aortic stenosis, and enhanced venous thromboembolism. Lp(a)'s affinity for the aortic valve contributes to calcification and stenosis. Its pro-thrombotic properties can lead to blood clots, and its presence accelerates the build-up of plaque in arteries. The precise mechanisms driving these effects, including the role of oxidized phospholipids carried by Lp(a), are still under investigation.
THERAPEUTIC STRATEGIES FOR ELEVATED LIPOPROTEIN(A)
Current treatment strategies for elevated Lp(a) are evolving. While apheresis can remove Lp(a), it's cumbersome and rarely used. Niacin may offer a modest reduction, but its clinical benefit is uncertain. Statins, crucial for managing LDL-C, do not significantly lower Lp(a). However, PCSK9 inhibitors have shown promise, reducing Lp(a) by 30-50%. Looking ahead, antisense oligonucleotides (ASOs) represent a breakthrough, directly inhibiting apoA synthesis and offering substantial reductions in Lp(a) levels.
LIFESTYLE MODIFICATIONS AND FUTURE DIRECTIONS
Unlike other lipid markers, Lp(a) is largely resistant to lifestyle interventions such as diet and exercise. While managing other risk factors like LDL-C with statins is vital, it does not address elevated Lp(a) directly. The development of targeted therapies like PCSK9 inhibitors and ASOs marks a significant advancement in managing Lp(a)-related cardiovascular risk. Ongoing research aims to further elucidate the complex role of Lp(a) and refine treatment approaches.
Mentioned in This Episode
●Supplements
●Products
●Software & Apps
●Companies
●Organizations
●Drugs & Medications
●Studies Cited
●Concepts
●People Referenced
Common Questions
Lp(a) (Lipoprotein(a)) is a particle that is a subset of LDL, but with an additional protein called Apo(a) attached. High levels of Lp(a) are a significant, genetically determined risk factor for atherosclerosis, aortic stenosis, and venous thrombosis, often independent of other risk factors.
Topics
Mentioned in this video
A molecule that Apo(a) resembles, suggesting potential roles in clotting and fibrinolysis.
An anatomical variation of the aortic valve (two leaflets instead of three) that predisposes individuals to aortic stenosis, especially when combined with elevated Lp(a).
A condition involving blood clots in deep veins, with elevated Lp(a) increasing the risk.
Repeating structural domains within Apo(a) and plasminogen, with variability in Kringle 4, subsection 2 being significant for Lp(a) mass and size.
The preferred method for quantifying Lp(a) risk, aiming for levels below 50 nmol/L.
A type of fat suggested as a beneficial replacement for saturated fat, particularly for individuals on a ketogenic diet experiencing elevated LDL-P.
Likely the primary receptor responsible for clearing Lp(a) from the bloodstream.
A high-fat diet discussed in relation to its potential impact on lipids, particularly LDL-P, which can increase significantly for some individuals due to saturated fat intake.
An alternative topic suggested for the podcast, which received significant interest but was ultimately superseded by Lp(a) based on audience poll.
A variant of Apolipoprotein E that was protective against parasitic infections but increases Alzheimer's risk in modern times.
A more accurate imaging modality than echocardiogram for assessing aortic valve morphology and pressure gradients, recommended for patients with elevated Lp(a).
Essential molecule for cellular membranes and hormone production, which needs to be transported in the bloodstream via lipoproteins.
A condition where the aortic valve narrows, significantly associated with elevated Lp(a) levels.
The apolipoprotein found on HDL particles, distinct from ApoB100 on LDL, contributing to HDL's non-atherogenic properties.
Blood clots in veins, with elevated Lp(a) conferring approximately a 3x increased hazard ratio for these events.
Molecules that Apo(a) can bind to, contributing to inflammation and vascular damage; their levels, normalized for ApoB, can serve as a proxy for Lp(a) risk.
Brain Natriuretic Peptide, a blood marker used in ERs to assess for cardiomyopathy or cardiac failure, a sign that can be associated with aortic stenosis.
Publication that featured an article by Anahad O'Connor about Lp(a), bringing wider attention to this heart risk factor.
Mentioned in the context of the complexity and interconnectedness of biological systems, akin to the Dunning-Kruger effect in understanding Lp(a).
A statin medication that, according to some studies, may trend towards increasing Lp(a) levels.
A statin medication potentially associated with trending Lp(a) levels.
A class of drugs designed to lower Lp(a) by disrupting the synthesis of Apo(a) in the liver; showing high efficacy in clinical trials.
Medications primarily used to lower LDL cholesterol by upregulating LDL receptors in the liver. They generally do not lower Lp(a) but are crucial for managing LDL targets in patients with elevated Lp(a).
A statin medication potentially associated with trending Lp(a) levels.
A statin medication that, according to some studies, may trend towards increasing Lp(a) levels.
A class of drugs that lower LDL and can reduce Lp(a) by approximately 30-50%, by inhibiting PCSK9 which degrades LDL receptors and potentially other Lp(a) clearance receptors.
A statin medication potentially associated with trending Lp(a) levels.
Interviewer for the podcast episode on Lp(a).
Considered a world expert on Lp(a), whose insights and research are frequently referenced.
Author of a New York Times article that highlighted Lp(a) as an underrecognized heart risk factor.
A figure from 'The Biggest Loser' who had a heart attack at age 52, attributed partly to high Lp(a) levels.
A researcher whose work and explanations are cited regarding the mechanism of statins and Lp(a), and the hypothesis on saturated fat's effect on cholesterol synthesis.
More from Peter Attia MD
View all 322 summaries
135 min381‒Alzheimer’s disease in women: how hormonal transitions impact the brain, new therapies, & more
9 minIs Industrial Processing the Real Problem With Seed Oils? | Layne Norton, Ph.D.
13 minCooking with Lard vs Seed Oils | Layne Norton, Ph.D.
146 min380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats?
Found this useful? Build your knowledge library
Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.
Try Summify free